AVNS vs HRTX
AVNS: Avanos Medical delivers non-opioid pain management and specialized nutrition feeding devices to hospitals and home care providers, reducing opioid dependency and supporting nutritional therapy across patient recovery pathways. HRTX: A commercial-stage biotech company bringing specialized injectable medicines to acute care and oncology settings, with a focus on non-opioid pain management and prevention of nausea in surgical and chemotherapy patients.
Side-by-side fundamentals
| Metric | AVNS | HRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.98 | $0.47 | |
| Market cap as of 2026-07-23 | $1.2B | $90M | |
| PEG as of 2026-07-23 | n/a | -0.01 | |
| Net margin as of 2026-07-23 | -10.4% | -20.5% | AVNS higher |
| Gross margin as of 2026-07-23 | +50.0% | +71.1% | HRTX higher |
| Operating margin as of 2026-07-23 | -8.8% | -14.5% | AVNS higher |
| ROE as of 2026-07-23 | -9.6% | -223.4% | AVNS higher |
| ROA as of 2026-07-23 | -7.0% | -12.6% | AVNS higher |
| Debt / equity as of 2026-07-23 | 0.13 | 15.50 | AVNS lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.9% | +1.5% | AVNS higher |
| Revenue CAGR (3y) SEC XBRL | +0.8% | n/a | |
| Beta as of 2026-07-23 | 1.60 | 1.69 | |
| 1-year return as of 2026-07-22 close | +111.2% | -75.1% | AVNS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.